Clinical trialPhase 2Active not recruiting
Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer
A Randomized Phase II Study of the Efficacy and Safety of Hypofractionated Stereotactic Radiotherapy and 5FU or Capecitabine With and Without Zometa in Patients With Locally Advanced Pancreatic Adenocarcinoma
- Outcome
- Ongoing. Results posted; no analysis attached
- Phase
- Phase 2
- Status
- Active not recruiting
- Study type
- Interventional
- Start
- 23 March 2017
- Expected end
- December 2027
- Enrollment
- 46 participants
- Sites
- 1
- Primary outcomes
- Local Control With and Without Zometa at Four Months in Follow-up; Local Control With and Without Zometa at Eight Months in Follow-up; Local Control With and Without Zometa at Twelve Months in Follow-up
- Sponsor type
- Academic / other
- Results posted
- 4 November 2026
- Last update
- 4 November 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Results
- Primary endpoint
- Results posted; no analysis attachedAs posted on ClinicalTrials.gov ↗, registry record of 4 November 2026
- Primary outcome
- Local Control With and Without Zometa at Four Months in Follow-upArm A (Chemotherapy, Radiation Therapy): 22, n = 22Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy): 19, n = 20Values: participantsTime frame: At 4 months in follow-upNo analysis posted for this outcome (outcome 1)
- Primary outcome
- Local Control With and Without Zometa at Eight Months in Follow-upArm A (Chemotherapy, Radiation Therapy): 19, n = 22Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy): 18, n = 20Values: participantsTime frame: At 8 months in follow-upNo analysis posted for this outcome (outcome 2)
- Primary outcome
- Local Control With and Without Zometa at Twelve Months in Follow-upArm A (Chemotherapy, Radiation Therapy): 19, n = 22Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy): 17, n = 20Values: participantsTime frame: At 12 months in follow-upNo analysis posted for this outcome (outcome 3)
- Participants
- Arm A (Chemotherapy, Radiation Therapy): 23 started, 22 completedArm B (Zoledronic Acid, Chemotherapy, Radiation Therapy): 23 started, 20 completed
- Serious adverse events
- Arm A (Chemotherapy, Radiation Therapy): 4 of 22Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy): 2 of 20Participants with at least one serious adverse event, of those at risk, as posted
6 secondary outcomes, the first 5 shown
- Grade 3 and Above Adverse Events With and Without Zoledronic Acid
- Arm A (Chemotherapy, Radiation Therapy) 7, n=22; Arm B (Zoledronic Acid, Chemotherapy, R… 6, n=20 [participants]
- Failure-free Survival With and Without Zometa
- Arm A (Chemotherapy, Radiation Therapy) 11 (6.1 to 18.5), n=22; Arm B (Zoledronic Acid, Chemotherapy, R… 8 (2.4 to 13.6), n=20 [median Month, 90% Confidence Interval]
- OS · Overall Survival With and Without Zometa
- Arm A (Chemotherapy, Radiation Therapy) 23.9 (11.5 to 30), n=22; Arm B (Zoledronic Acid, Chemotherapy, R… 26.1 (9 to 35.3), n=20 [median Month, 90% Confidence Interval]
- Surgically Complete Resection Rate With and Without Zometa
- Arm A (Chemotherapy, Radiation Therapy) 9/22; Arm B (Zoledronic Acid, Chemotherapy, R… 8/20 [Participants]
- Pathologic Response After Resection With and Without Zometa
- Arm A (Chemotherapy, Radiation Therapy) 4 (3 to 7), n=9; Arm B (Zoledronic Acid, Chemotherapy, R… 4 (3 to 9), n=8 [median score, Full Range]
Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
Pancreatic cancer, most commonly adenocarcinoma, is the fourth leading cause of cancer death in the United States. The mainstay of management centers on surgical resection (if resectable) and although low (15% to 20%), resectability rates are associated with dismal survival. An estimated 80% to 85% of the patients recur after surgical resection, leading to a median survival of 20 to 24 months and potentially even less depending on lymph nodal involvement or positive margins. The rationale for utilizing neoadjuvant therapy, commonly fluoropyrimidine-based or gemcitabine based chemotherapy or Chemoradiotherapy (CRT), involves possibly down staging borderline resectable and unresectable patients, potentially making them resectable candidates. This randomized phase II trial will study how well hypofractionated stereotactic body radiation therapy (SBRT) and fluorouracil or capecitabine with or without zoledronic acid work in treating participants with pancreatic cancer that has spread to nearby tissue or lymph nodes. Hypofractionated stereotactic body radiation therapy is a specialized radiation therapy that sends higher doses of x-rays over a shorter period of time directly to the tumor using smaller doses over several days which may cause less damage to normal tissue. Drugs used in chemotherapy, such as fluorouracil and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Zoledronic acid is used in cancer patients to reduce cancer symptoms and may make tumor cells more sensitive to radiation. Giving hypofractionated stereotactic body radiation therapy and fluorouracil or capecitabine with or without zoledronic acid may work better in treating pancreatic cancer.
Detailed description public domain (ClinicalTrials.gov)
Pancreatic cancer, most commonly adenocarcinoma, is the fourth leading cause of cancer death in the United States. The mainstay of management centers on surgical resection (if resectable) and although low (15% to 20%), resectability rates are associated with dismal survival. An estimated 80% to 85% of the patients recur after surgical resection, leading to a median survival of 20 to 24 months and potentially even less depending on lymph nodal involvement or positive margins. The rationale for utilizing neoadjuvant therapy, commonly fluoropyrimidine-based or gemcitabine based chemotherapy or Chemoradiotherapy (CRT), involves possibly down staging borderline resectable and unresectable patients, potentially making them resectable candidates. This randomized phase II trial will study how well hypofractionated stereotactic body radiation therapy (SBRT) and fluorouracil or capecitabine with or without zoledronic acid work in treating participants with pancreatic cancer that has spread to nearby tissue or lymph nodes. Hypofractionated stereotactic body radiation therapy is a specialized radiation therapy that sends higher doses of x-rays over a shorter period of time directly to the tumor using smaller doses over several days which may cause less damage to normal tissue. Drugs used in chemotherapy, such as fluorouracil and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Zoledronic acid is used in cancer patients to reduce cancer symptoms and may make tumor cells more sensitive to radiation. Giving hypofractionated stereotactic body radiation therapy and fluorouracil or capecitabine with or without zoledronic acid may work better in treating pancreatic cancer. The primary study objective is to evaluate the efficacy of hypofractionated radiation therapy concurrently with zoledronic acid (Zometa) and fluorouracil or capecitabine. Other study objectives include examining the toxicity of Zometa when used concurrently with hypofractionated radiation therapy, evaluating local failure-free survival and overall survival, determining surgical resection and tumor response rates, measuring Zometa pharmacokinetics, evaluating tumor and organ motion and determining the effect those on the dosimetry, local control and survival. Post-treatment follow-up is for 30 days, then every 3 months for the first year, every 4 months for the second year, and every 6 months thereafter.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Local Control With and Without Zometa at Four Months in Follow-up [At 4 months in follow-up]. Number, participants. Arm A (Chemotherapy, Radiation Therapy) (n=22): 22; Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy) (n=20): 19.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Local Control With and Without Zometa at Eight Months in Follow-up [At 8 months in follow-up]. Number, participants. Arm A (Chemotherapy, Radiation Therapy) (n=22): 19; Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy) (n=20): 18.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Local Control With and Without Zometa at Twelve Months in Follow-up [At 12 months in follow-up]. Number, participants. Arm A (Chemotherapy, Radiation Therapy) (n=22): 19; Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy) (n=20): 17.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Grade 3 and Above Adverse Events With and Without Zoledronic Acid [Up to 30 days after treatment]. Number, participants. Arm A (Chemotherapy, Radiation Therapy) (n=22): 7; Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy) (n=20): 6.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Failure-free Survival With and Without Zometa [From date of administration of study drug to the date of any failure, assessed up to 5 years]. Median, Month (90% Confidence Interval). Arm A (Chemotherapy, Radiation Therapy) (n=22): 11 (6.1 to 18.5); Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy) (n=20): 8 (2.4 to 13.6).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Overall Survival With and Without Zometa [From date of administration of study drug to the date of death, assessed up to 5 years]. Median, Month (90% Confidence Interval). Arm A (Chemotherapy, Radiation Therapy) (n=22): 23.9 (11.5 to 30); Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy) (n=20): 26.1 (9 to 35.3).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Surgically Complete Resection Rate With and Without Zometa [Immediately after surgery]. Count Of Participants, Participants. Arm A (Chemotherapy, Radiation Therapy) (n=22): 9; Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy) (n=20): 8.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Pathologic Response After Resection With and Without Zometa [Immediately after surgery]. Median, score (Full Range). Arm A (Chemotherapy, Radiation Therapy) (n=9): 4 (3 to 7); Arm B (Zoledronic Acid, Chemotherapy, Radiation Therapy) (n=8): 4 (3 to 9).